News
BLRX
0.5753
-6.15%
-0.0377
Weekly Report: what happened at BLRX last week (0415-0419)?
Weekly Report · 4d ago
BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 04/17 17:44
Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency
TipRanks · 04/17 15:05
BioLineRx Enhances Multiple Myeloma Treatment
TipRanks · 04/17 12:27
Weekly Report: what happened at BLRX last week (0408-0412)?
Weekly Report · 04/15 10:17
Biolinerx: Report of foreign issuer
Press release · 04/10 12:05
BIOLINERX ACCESSES SECOND TRANCHE OF $20 MILLION UNDER PREVIOUSLY ANNOUNCED $40 MILLION NON-DILUTIVE DEBT FINANCING AGREEMENT
Reuters · 04/10 11:00
Weekly Report: what happened at BLRX last week (0401-0405)?
Weekly Report · 04/08 10:20
BUZZ-U.S. STOCKS ON THE MOVE-Eiger BioPharmaceuticals, Reddit, US energy sector
Stronger-than-expected manufacturing data propped up Treasury yields and tempered expectations of a rate cut in June. The Dow Jones Industrial Average was down 0.75% in midday trading on Monday. The top three S&P 500 percentage gainers were Micron Technology, Wynn Resorts.
Reuters · 04/01 17:47
BUZZ-U.S. STOCKS ON THE MOVE-Trump Media & Technology, Semtech, General Dynamics
The tech-heavy Nasdaq outpaced Wall Street peers on Monday as megacap growth stocks gained on hopes of an early rate cut by the Fed. The Dow Jones Industrial Average was down 0.63% at 39,555.06. The top three S&P 500 percentage gainers were Micron Technology, Wynn Resorts.
Reuters · 04/01 15:50
BiolineRx Ltd. Completes Significant Securities Offering
TipRanks · 04/01 15:27
BioLineRx to raise $6M through a direct offering
BioLineRx to raise $6M through a direct offering. The company will offer 7.5M of its American depositary shares and warrants in the offering. Each ADS represents 15 ordinary shares of BioLineRX Ltd. (BLRX) Stock.
Seeking Alpha · 04/01 13:14
BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant
BioLineRx Ltd. Intends to use the net proceeds from the offering to support the commercialization of APHEXDA. The company is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The offering is expected to close in 2024.
Benzinga · 04/01 13:02
BIOLINE RX LTD <BLRX.TA> - DIRECT OFFERING OF 7.5 MLN OF ADSS AND WARRANTS AT A COMBINED PURCHASE PRICE OF $0.80 PER ADS AND ACCOMPANYING WARRANT
Reuters · 04/01 13:00
Weekly Report: what happened at BLRX last week (0325-0329)?
Weekly Report · 04/01 10:19
BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 03/26 16:23
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
Benzinga · 03/26 16:12
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
BioLine Rx reported earnings per share of -15 cents. The company reported revenue of $4.80 million. This was above the analyst estimate for EPS of -22 cents. BioLine Rx was down 2% in after-hours trading on Thursday. The stock is down 7% in the past week.
Investorplace · 03/26 15:53
Buy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst Optimism
TipRanks · 03/26 15:45
BioLine Rx Q4 EPS $(0.15) Beats $(0.22) Estimate, Sales $4.80M
Benzinga · 03/26 13:28
More
Webull provides a variety of real-time BLRX stock news. You can receive the latest news about Biolinerx through multiple platforms. This information may help you make smarter investment decisions.
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.